#RNL2023 @RheumNow There are a lot of RA Rx on market now - do we need more? Dr. Brenner: YES Stromal targets like LIF/LIFR, Notch3, cadherin-11 offer upstream benefits for our difficult to treat RA patients that don't respond to tradition cs/bDMARDs https://t.co/xavJrFX84G https://t.co/gAdMU4AgXz